Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME GONZALEZ

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1477848695
CMS profile
519585
Location
EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,130.74

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,093.46 63
Education $37.28 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME GONZALEZ

NPI 1477848695 · CMS profile ID 519585

Allopathic & Osteopathic Physicians / Internal Medicine

EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477848695?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME GONZALEZ, NPI 1477848695, CMS profile ID 519585. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477848695?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAIME GONZALEZ, NPI 1477848695, CMS profile ID 519585. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477848695?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAIME GONZALEZ, NPI 1477848695, CMS profile ID 519585, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1477848695?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $1,130.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $23.2403/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228639433 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.4702/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223001674 CMS
Novo Nordisk Inc $22.3402/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188918811 CMS
Calliditas Therapeutics US Inc. $16.3502/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234996745 CMS
Novo Nordisk Inc $21.6602/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189020964 CMS
Calliditas Therapeutics US Inc. $4.8502/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234996743 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.2902/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225554499 CMS
Travere Therapeutics, Inc. $6.4402/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244440189 CMS
Novo Nordisk Inc $19.0302/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189119760 CMS
OPKO Pharmaceuticals, LLC $17.4901/31/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1222081147 CMS
Calliditas Therapeutics US Inc. $2.8401/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234996737 CMS
Calliditas Therapeutics US Inc. $4.7101/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234996739 CMS
Calliditas Therapeutics US Inc. $27.1801/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234996741 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1201/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223001672 CMS
Travere Therapeutics, Inc. $24.4101/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244440197 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $231.90 29
PY2020 $281.03 10
PY2021 $506.01 39
PY2022 $2,331.47 41
PY2023 $675.99 32
PY2024 $767.66 43
PY2025 $1,130.74 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,236,879.90 178
PY2024 Principal investigator $130,616.61 26
PY2023 Principal investigator $6,925.09 4
PY2022 Principal investigator $18,743.86 3
PY2021 Principal investigator $31,437.30 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

178 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $14,066.00 12/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678262
Principal investigator 1 CSL Behring $204.00 12/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678288
Principal investigator 1 CSL Behring $204.00 12/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678290
Principal investigator 1 CSL Behring $355.00 12/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678292
Principal investigator 1 CSL Behring $507.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678698
Principal investigator 1 CSL Behring $845.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678700
Principal investigator 1 CSL Behring $1,406.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678702
Principal investigator 1 CSL Behring $75.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678706
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678708
Principal investigator 1 CSL Behring $136.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678710
Principal investigator 1 CSL Behring $150.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678712
Principal investigator 1 CSL Behring $169.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678714
Principal investigator 1 CSL Behring $204.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678716
Principal investigator 1 CSL Behring $204.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678718
Principal investigator 1 CSL Behring $300.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678720
Principal investigator 1 CSL Behring $355.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678722
Principal investigator 1 CSL Behring $355.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678724
Principal investigator 1 CSL Behring $680.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678726
Principal investigator 1 CSL Behring $710.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678728
Principal investigator 1 CSL Behring $1,606.00 12/05/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678730
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841621
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841687
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841689
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841691
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841693
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841695
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841697
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842127
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842129
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842131
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842133
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842135
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842137
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842139
Principal investigator 1 AKEBIA THERAPEUTICS INC $917.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842141
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842143
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842365
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842367
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842369
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842371
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842373
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842375
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522270
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,144.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522272
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,040.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522274
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522276
Principal investigator 1 Alnylam Pharmaceuticals Inc. $780.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522278
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,230.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522280
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,714.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522282
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,840.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522284
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,448.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522286
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522288
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522290
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522292
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522294
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,014.00 11/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522296
Principal investigator 1 CSL Behring $5,544.00 11/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679042
Principal investigator 1 AKEBIA THERAPEUTICS INC $685.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841619
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842822
Principal investigator 1 AKEBIA THERAPEUTICS INC $293.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842934
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843070
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843072
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843074
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843076
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843214
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843216
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843218
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843220
Principal investigator 1 AKEBIA THERAPEUTICS INC $360.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845446
Principal investigator 1 AKEBIA THERAPEUTICS INC $85.00 11/05/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845465
Principal investigator 1 CSL Behring $14,510.00 10/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678926
Principal investigator 2 CSL Behring $671,512.00 10/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679044
Principal investigator 1 CSL Behring $225.00 10/15/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678889
Principal investigator 1 CSL Behring $676.00 10/15/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678891
Principal investigator 1 CSL Behring $3,057.00 10/15/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678893
Principal investigator 1 CSL Behring $408.00 10/15/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679030
Principal investigator 1 CSL Behring $82.00 10/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678845
Principal investigator 1 CSL Behring $338.00 10/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678847
Principal investigator 1 CSL Behring $3,510.00 10/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678849
Principal investigator 1 CSL Behring $441.19 10/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678228
Principal investigator 1 CSL Behring $204.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679202
Principal investigator 1 CSL Behring $204.00 10/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679204
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841407
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841409
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841411
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841879
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841881
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841883
Principal investigator 1 AKEBIA THERAPEUTICS INC $764.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841885
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841887
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841889
Principal investigator 1 AKEBIA THERAPEUTICS INC $801.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241841891
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842491
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842527
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842572
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842600
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842608
Principal investigator 1 AKEBIA THERAPEUTICS INC $213.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842610
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842664
Principal investigator 1 AKEBIA THERAPEUTICS INC $338.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842666
Principal investigator 1 AKEBIA THERAPEUTICS INC $213.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842708
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843358
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843360
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843362
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843364
Principal investigator 1 AKEBIA THERAPEUTICS INC $410.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845230
Principal investigator 1 AKEBIA THERAPEUTICS INC $100.00 10/03/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845290
Principal investigator 1 CSL Behring $300.00 10/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679126
Principal investigator 1 CSL Behring $1,014.00 10/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679128
Principal investigator 1 CSL Behring $300.00 10/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679180
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,000.00 10/01/2025 Non-covered Recipient Entity
EL PASO KIDNEY SPECIALISTS
Cardiovascular Renal and Metabolism Lokelma Hyperkalemia No dispute reported 06/30/2026 1185547071
Principal investigator 2 CSL Behring $495,933.00 09/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679230
Principal investigator 1 CSL Behring $19,638.00 09/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252679088
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843502
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843504
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843506
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843508
Principal investigator 1 AKEBIA THERAPEUTICS INC $82.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845133
Principal investigator 1 AKEBIA THERAPEUTICS INC $20.00 09/10/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845195
Principal investigator 1 CSL Behring $408.00 09/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673696
Principal investigator 1 CSL Behring $7,916.00 09/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673698
Principal investigator 1 CSL Behring $204.00 09/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673764
Principal investigator 1 CSL Behring $32,641.00 08/20/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673636
Principal investigator 1 CSL Behring $696,840.00 08/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673784
Principal investigator 1 CSL Behring $562.13 08/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678172
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843666
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843670
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843674
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843677
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843926
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843930
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843934
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843938
Principal investigator 1 AKEBIA THERAPEUTICS INC $205.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845030
Principal investigator 1 AKEBIA THERAPEUTICS INC $50.00 08/06/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241845089
Principal investigator 1 CSL Behring $16.71 08/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678198
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844501
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844505
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844509
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844513
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844608
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844611
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844615
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844619
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844622
Principal investigator 1 AKEBIA THERAPEUTICS INC $759.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844627
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,362.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844630
Principal investigator 1 AKEBIA THERAPEUTICS INC $912.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844638
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,480.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844641
Principal investigator 1 AKEBIA THERAPEUTICS INC $360.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844645
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,767.00 07/23/2025 Non-covered Recipient Entity
El Paso Kidney Specialists, PA
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844649
Principal investigator 1 CSL Behring $81,784.00 07/16/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673908
Principal investigator 1 CSL Behring $75.00 07/09/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673968
Principal investigator 1 CSL Behring $82.00 07/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673868
Principal investigator 1 CSL Behring $150.00 07/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673870
Principal investigator 1 CSL Behring $338.00 07/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673872
Principal investigator 1 CSL Behring $1,420.00 07/07/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673874
Principal investigator 1 CSL Behring $7,965.00 06/30/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673848
Principal investigator 1 CSL Behring $94.69 06/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678114
Principal investigator 1 CSL Behring $2,223.71 06/12/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678104
Principal investigator 1 Alnylam Pharmaceuticals Inc. $120.00 05/28/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522390
Principal investigator 1 CSL Behring $151.32 05/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678084
Principal investigator 1 CSL Behring $1,977.00 05/14/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673820
Principal investigator 5 CSL Behring $968.00 05/14/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673976
Principal investigator 1 CSL Behring $13,684.00 04/16/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674158
Principal investigator 1 CSL Behring $121.08 04/11/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678052
Principal investigator 1 CSL Behring $16.71 04/11/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678130
Principal investigator 1 CSL Behring $16.71 04/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678118
Principal investigator 1 CSL Behring $665.92 04/08/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678438
Principal investigator 1 CSL Behring $3,954.00 03/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674128
Principal investigator 1 CSL Behring $105.92 03/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678384
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26,545.00 02/21/2025 Non-covered Recipient Entity
Total Renal Research Inc.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215522374
Principal investigator 1 CSL Behring $12,359.00 02/19/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674100
Principal investigator 1 CSL Behring $362.63 02/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678352
Principal investigator 1 CSL Behring $728.18 02/06/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252678330
Principal investigator 1 CSL Behring $8,140.00 01/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674052
Principal investigator 1 CSL Behring $14,303.00 01/10/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674162